Lorus Therapeutics Inc.
| Change | -0.01 | -4.55% |
| Volume | 10,244 | |
| 52 week | Low | Hi |
| $0.16 | $1.03 | |
| Financial Information | |
| Shares Outstanding: | 21,168,746 |
| (As per management) | |
| Fully Diluted Shares: | 32,000,000 |
| (As per management) | |
| Est. Market Float: | 9,000,000 |
| Market Cap.: | $4,445,437 |
| Last Declared Dividend: | - |
| EPS last 3 months : | $(0.06) |
| EPS Trailing 12 months: | $(0.38) |
| (As per management) | |
| Long-Term Debt: | - |
| Financial Year-End: | May 31 |
15-20 minutes delay
Renmark Financial Disclaimer
This document is published for general information only and it should not be interpreted as an investment recommendation nor an offer or a solicitation to buy or sell securities issued by the said company. Renmark does not and will not accept any responsibility or liability for investment decisions made on the basis of the information herein contained.
Lorus Therapeutics Inc. is a biopharmaceutical company focused on the discovery, research and development of novel, first-in-class anticancer therapies with high safety profiles. Through its own discovery efforts, as well as partnering activities, Lorus is building a portfolio of promising anticancer drugs ranging from discovery and preclinical to clinical-proof-of concept stage. Lorus seeks suitable partners for subsequent late-stage registration trials and eventual commercialization.
Dr. Aiping H. Young, MD, PhD - President and Chief Executive Officer
Dr. Yoon Lee, PhD - Vice President, Research
Elizabeth Williams, CA - Director of Finance and Administration (Acting CFO)
Peter Murray - Director, Clinical Development
Dr. Jim A. Wright - Chairman
Dr. Denis Burger - Director
Herbert Abramson - Director
Warren Whitehead - Director
Dr. Mark Vincent - Director
Dr. Aiping H. Young - Director
- Interview request
- Media Information
- Company Factsheet
- SEDAR filings
Headquarters:
2 Meridian RoadToronto, Ontario
M9W 4Z7 Canada